• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

by Fred Pennic 05/20/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
White House, IBM Partner to Fight COVID-19 Using Supercomputers

What You Should Know: 

– The U.S. Department of Health and Human Services (HHS) announced it is taking immediate action to implement President Donald J. Trump’s Executive Order, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” 

– Under the leadership of President Trump, HHS Secretary Robert F. Kennedy Jr., and Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz, the Department has outlined specific targets for pharmaceutical manufacturers. 

– The administration anticipates highlighting these commitments in the coming weeks, with the goal of ensuring Americans no longer face higher medication costs than patients in economically comparable nations.

The Most-Favored-Nation Pricing Mandate

HHS expects pharmaceutical manufacturers to commit to aligning U.S. prices for all brand-name products that do not currently face generic or biosimilar competition with the lowest price found among a set of peer countries. The Most-Favored-Nation (MFN) target price is defined as the lowest price in an Organisation for Economic Co-operation and Development (OECD) country that has a GDP per capita of at least 60 percent of the U.S. GDP per capita.

Expected Impact: Lower Costs While Aiming to Preserve Innovation

Officials state that these targets are designed to drastically reduce U.S. drug prices, which are often reported to be three to five times higher than those abroad. The administration asserts that this policy will relieve an unfair financial burden on Americans while preserving innovation, by ensuring U.S. patients do not bear a greater cost for the same drugs than patients in other developed nations. 

The administration frames the move as a necessary step to correct an unfair burden on U.S. consumers. “For too long, Americans have been forced to pay exorbitant prices for the same drugs that are sold overseas for far less,” said Secretary Kennedy. “That ends today. We expect pharmaceutical manufacturers to fulfill their commitment to lower prices for American patients, or we will take action to ensure they do.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

HIMSS26 Wrap-Up

HIMSS26 Wednesday Wrap-Up: Scaling Agentic AI, Securing the Enterprise, and Fixing Hospital Finance

Most-Read

Health Recovery Solutions (HRS) Acquires Rimidi for Chronic Care Management and RPM Integration

Health Recovery Solutions (HRS) Acquires Rimidi for Chronic Care Management and RPM Integration

RadNet Subsidiary DeepHealth Acquires French Radiology AI Leader Gleamer

RadNet’s $269M AI Play: DeepHealth Acquires French AI Gleamer

Walgreens Launches Virtual Weight Management Platform for Self-Pay GLP-1 Patients

Walgreens Launches Virtual Weight Management Platform for Self-Pay GLP-1 Patients

KLAS Digital Pathology 2026 Report: Top IMS, Scanner, and AI Vendors Evaluated

KLAS Digital Pathology 2026 Report: Top IMS, Scanner, and AI Vendors Evaluated

The "Platform" Squeeze: Epic Releases Native AI Charting, Putting Venture-Backed Scribes on Notice

The “Platform” Squeeze: Epic Releases Native AI Charting, Putting Venture-Backed Scribes on Notice

Analysis: Oracle Cerner’s Plans for a National EHR

Oracle May Cut 30k Jobs and Sell Cerner to Fund $156B OpenAI Deal

The $1.9B Exit: Why CommonSpirit is Insourcing Revenue Cycle and Tenet is Betting Big on Conifer AI

The $1.9B Exit: Why CommonSpirit is Insourcing Revenue Cycle and Tenet is Betting Big on Conifer AI

KLAS 2026 Rankings: Aledade and Guidehealth Named Top VBC Enablement Firms

KLAS 2026 Rankings: Aledade and Guidehealth Named Top VBC Enablement Firms

Beyond the Hype: New KLAS Data Validates the Financial and Clinical ROI of Ambient AI

Beyond the Hype: New KLAS Data Validates the Financial and Clinical ROI of Ambient AI

Anthropic Debuts ‘Claude for Healthcare’ and Opus 4.5 to Engineer the Future of Life Sciences

Anthropic Debuts ‘Claude for Healthcare’ and Opus 4.5 to Engineer the Future of Life Sciences

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |